Elke A. Van Gorp
Bilthoven, UT, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Clinical use of ampicillin-sulbactam/ceftazidime-avibactam combination therapy for carbapenem-resistant Acinetobacter baumannii complex infections.
Journal: Antimicrobial agents and chemotherapy
Published: August 27, 2026
Correction: Ambler class C-type β-lactamases and porin alterations in Enterobacter cloacae complex and Klebsiella aerogenes in the Netherlands, 2012-2023.
Journal: BMC microbiology
Published: March 28, 2026
Ambler class C-type β-lactamases and porin alterations in Enterobacter cloacae complex and Klebsiella aerogenes in the Netherlands, 2012-2023.
Journal: BMC microbiology
Published: April 07, 2025
Ambler class C-type β-lactamases and porin alterations in Enterobacter cloacae complex and Klebsiella aerogenes in the Netherlands, 2012-2023.
Journal: BMC microbiology
Published: April 07, 2025
Oral ciprofloxacin biofilm activity in a catheter-associated urinary tract infection model.
Journal: The Journal of antimicrobial chemotherapy
Published: August 23, 2024
Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model.
Journal: The Journal of antimicrobial chemotherapy
Published: September 01, 2022
Attributable mortality and excess length of stay associated with third-generation cephalosporin-resistant Enterobacterales bloodstream infections: a prospective cohort study in Suva, Fiji.
Journal: Journal of global antimicrobial resistance
Published: May 23, 2022
Epidemiology, antimicrobial resistance and outcomes of Staphylococcus aureus bacteraemia in a tertiary hospital in Fiji: A prospective cohort study.
Journal: The Lancet regional health. Western Pacific
Published: April 04, 2022
Oral fosfomycin activity against Klebsiella pneumoniae in a dynamic bladder infection in vitro model.
Journal: The Journal of antimicrobial chemotherapy
Published: October 25, 2021
Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic In Vitro Model.
Journal: Antimicrobial agents and chemotherapy
Published: February 20, 2020
Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model.
Journal: The Journal of antimicrobial chemotherapy
Published: January 06, 2020
Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy.
Journal: Journal of microbiological methods
Published: October 25, 2019
Last Updated: 09/26/2026